Search results for "Treatment strategy"

showing 10 items of 40 documents

Two Great Intricate Gestational Syndromes. New Screening and Treatment Strategies

2020

Abstract Gestational hypertension and premature birth frequently and independently affect the pregnancy prognosis with potentially detrimental influence of the pregnancy evolution. Pregnancy-induced hypertension, spectrum and categories of the systemic disease: gestational hypertension, preeclampsia, eclamsia, Hellp syndrome, overlapping preeclampsia (PE) chronic arterial hypertension, are some of the complications that can occur over the pregnancy evolution. Annually, preeclampsia affects approximately 4 million pregnancies. According to ACOG, preeclampsia complicates the evolution of pregnancies in a 2-8% ratio. According to WHO and FIGO, premature birth occurs after 37 weeks of complete …

03 medical and health sciencesPediatricsmedicine.medical_specialty030219 obstetrics & reproductive medicine0302 clinical medicinebusiness.industryMedicineGestationTreatment strategy030212 general & internal medicineGeneral MedicinebusinessActa Medica Transilvanica
researchProduct

Treatment strategies for lysosomal storage disorders.

2017

Over the past several years the number of treatments available for patients with lysosomal storage disorders has rapidly increased. Haematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction, and chaperone therapies are currently available, and gene therapies and other treatments are rapidly advancing. Despite remarkable advances, the efficacy of most of these therapies is limited, particularly because the treatments are usually initiated when organ damage has already occurred. To circumvent this limitation, screening in newborn infants for lysosomal storage disorders has been introduced in many countries. However, this screening is complicated by the broad cl…

0301 basic medicineGenetic enhancementLysosomal storage disordersBioinformatics03 medical and health sciences0302 clinical medicineDevelopmental NeuroscienceSlow progressionMedicineHumansEnzyme Replacement Therapybusiness.industryHematopoietic Stem Cell TransplantationEnzyme replacement therapyGenetic TherapyOrgan damageTransplantationLysosomal Storage Diseases030104 developmental biologyPediatrics Perinatology and Child HealthImmunologyTreatment strategyNeurology (clinical)Stem cellbusiness030217 neurology & neurosurgeryMolecular ChaperonesDevelopmental medicine and child neurology
researchProduct

Heat shock protein: a hot topic in idiopathic pulmonary fibrosis

2017

HSP90 inhibition could be an exciting new treatment strategy for IPF http://ow.ly/HfKY306uvxw

0301 basic medicinePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyPulmonary Fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineHeat shock proteinPulmonary fibrosismedicineHumansHeat-Shock Proteinsbiologybusiness.industrymedicine.diseaseImmunohistochemistryHsp90Idiopathic Pulmonary Fibrosis030104 developmental biology030228 respiratory systemImmunologybiology.proteinImmunohistochemistryTreatment strategybusinessEuropean Respiratory Journal
researchProduct

Evaluation of Risk Stratification Markers and Models in Acute Pulmonary Embolism: Rationale and Design of the MARS-PE (Mainz Retrospective Study of P…

2018

An acute pulmonary embolism (PE) is a crucial event in patients’ life and connected with serious morbidity and mortality. Regarding a high case-fatality rate, early and accurate risk-stratification is crucial. Risk for mortality and complications are closely related to hemodynamic stability and cardiac adaptations. The currently recommended risk-stratification approach is not overall simple to use and might delay the identification of those patients, who should be monitored more closely and may treated with more aggressive treatment strategies. Additionally, some risk-stratification criteria for the imaging procedures are still imprecise. Summarized, the search for the most effective risk-s…

AdultDiagnostic ImagingMalemedicine.medical_specialtypulmonary embolismlcsh:Medicinerisk stratification030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness Index03 medical and health sciences0302 clinical medicinestudy designRisk FactorsGermanyMedicineHumansIn patientIntensive care medicineAgedRetrospective Studiesbusiness.industrylcsh:RRetrospective cohort studyImaging ProceduresGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolism030228 respiratory systemResearch DesignRisk stratificationAcute DiseaseoutcomeTreatment strategysymptomsFemaleHemodynamic stabilitybusinessBiomarkersActa Medica
researchProduct

Predictors of functional outcome after a manic episode.

2015

Abstract Background The identification of functional outcome predictors after acute episodes of bipolar disorders (BD) may allow designing appropriate treatment aiming at restoring psychosocial functioning. Our objective was to identify the best functional outcome predictors at a 6-month follow-up after an index manic episode. Methods We conducted a naturalistic trial (MANACOR) focusing on the global burden of BD, with special emphasis on manic episode-associated costs. We observed patients with BD seen in services of four hospitals in Catalonia (Spain).The total sample included 169 patients with chronic DSM-IV-TR BD I suffering from an acute manic episode who were followed-up for 6 months.…

AdultMalemedicine.medical_specialtyBipolar DisorderBody Mass IndexRecurrenceInternal medicinemedicineHumansBipolar disorderPsychiatryRetrospective StudiesStepwise regressionmedicine.diseaseOutcome (probability)Psychiatry and Mental healthClinical PsychologyTreatment OutcomeSocioeconomic FactorsSpainTreatment strategyFemalePredictive variablesPsychologyPsychosocialBody mass indexFollow-Up StudiesJournal of affective disorders
researchProduct

Untargeted Antifungal Treatment Strategies for Invasive Candidiasis in Non-neutropenic Critically Ill Patients: Current Evidence and Insights

2017

Purpose of Review: The purpose of this study was to provide an overview and insights on important new concepts on untargeted antifungal treatment strategies, namely prophylaxis pre-emptive and empiric treatments for the management of invasive candidiasis (IC) in non-neutropenic critically ill patients. Recent Findings: Recently, clinical practice guidelines provided recommendation for the management of IC. However, results from recent trials and systematic reviews questioned the effect of untargeted antifungal treatment strategies, especially in terms of survival benefits in non-neutropenic patients, even with septic shock. Summary: Widespread use of untargeted antifungal treatment strategi…

Antifungalmedicine.medical_specialtyEmpiric treatmentmedicine.drug_classInvasive candidiasiBiology03 medical and health sciences0302 clinical medicineInvasive fungal infectionmedicine030212 general & internal medicineAntifungal treatmentMED/41 - ANESTESIOLOGIAIntensive care medicineCandida infectionCritically illCandidemia030208 emergency & critical care medicineInvasive candidiasismedicine.diseaseNon neutropenicClinical PracticeInvasive candidiasisInfectious DiseasesSystematic reviewTreatment strategyAntifungal treatment; Candida infection; Candidemia; Empiric treatment; Invasive candidiasis; Invasive fungal infectionEmpiric treatment
researchProduct

Collateral Sensitivity in Drug-Resistant Tumor Cells

2013

Collateral sensitivity is a term for the hypersensitivity of otherwise drug-resistant cells. The selective killing of tumor cells by drugs exerting collateral sensitivity might be used as a novel treatment strategy. In this chapter, we give an overview on drug resistance phenotypes with known collateral sensitivities; furthermore, their molecular and cellular mechanisms were discussed to explain mediation of these hypersensitivities.

ChemotherapybiologyCollateralbusiness.industrymedicine.medical_treatmentTumor cellsDrug resistancePhenotypeMultiple drug resistancebiology.proteinmedicineCancer researchTreatment strategybusinessP-glycoprotein
researchProduct

Lactate and glucose as energy substrates and their role in traumatic brain injury and therapy

2009

Traumatic brain injury is a leading cause of disability and mortality worldwide, but no new pharmacological treatments are clinically available. A key pathophysiological development in the understanding of traumatic brain injury is the energy crisis derived from decreased cerebral blood flow, increased energy demand and mitochondrial dysfunction. Although still controversial, new findings suggest that brain cells try to cope in these conditions by metabolizing lactate as an energy substrate ‘on-demand’ in lieu of glucose. Experimental and clinical data suggest that lactate, at least when exogenously administered, is transported from astrocytes to neurons for neuronal utilization, essential…

Energy demandTraumatic brain injuryMetabolismPharmacologyBiologymedicine.diseasePathophysiologyNeurologyCerebral blood flowBiochemistrymedicineTreatment strategyGlycolysisNeurology (clinical)Future Neurology
researchProduct

Somatisierung - Konversion - Dissoziation: Verhaltenstherapeutische Therapiestrategien/ Somatization – Conversion – Dissociation: Strategies of Behav…

2005

Zusammenfassung Die modernen verhaltenstherapeutischen Ansatze zur Behandlung von Patienten mit unklaren korperlichen Symptomen haben sich auf der Grundlage der Klassifikationssysteme DSM-IV und ICD-10 entwickelt. Dort sind die somatoformen Storungen als einheitliche Storungsgruppe definiert. Erganzend zur deskriptiven Diagnostik hat die Verhaltenstherapie ein Storungsmodell entwickelt, welches atiologische, auslosende und aufrecht erhaltende Faktoren im Sinne eines Regelkreismodells beschreibt. Die therapeutischen Ziele und Strategien konnen konsequent aus diesem Modell abgeleitet werden. Zentrale Komponenten sind (1) die Motivierung des Patienten fur ein psychotherapeutisches Vorgehen, (2…

Gynecologymedicine.medical_specialtybusiness.industrymedicineTreatment strategymedicine.diseasebusinessSomatizationZeitschrift für Psychosomatische Medizin und Psychotherapie
researchProduct

Adefovir for lamivudine resistant HBV: More than meets the eye

2007

– In patients with LAM resistance and high levels of HBV-DNA, especially if HBeAg positive, it may be difficult to obtain a strong virological suppression with ADV. – Restrictive criteria are needed to define virological response (HBV-DNA < 10 3 copies/ml or 200 IU/ml). – Early finding of non-response or of suboptimal response after 9–12 months of ADV therapy suggests a high risk of emergence of ADV-resistant strains and should prompt a change of treatment strategy. In patients with cirrhosis, due to the risk of liver failure, treatment changes should be considered even earlier, at 3–6 months.

Hepatitis B virusmedicine.medical_specialtyCirrhosisHepatologybusiness.industryvirusesLiver failurevirus diseasesLamivudinemedicine.diseasemedicine.disease_causeGastroenterologyVirological responseInternal medicineImmunologyHBVmedicineAdefovirTreatment strategyIn patientbusinessmedicine.drugJournal of Hepatology
researchProduct